Low testosterone levels may be associated with increased risk of prostate cancer progression during surveillance
Study found men with low testosterone levels were associated with a 60% higher likelihood that prostate cancer managed on active surveillance would progress to a more aggressive state over time
Research challenges the long-held belief that high testosterone fuels early-stage prostate cancer growth, suggesting instead that low testosterone may be associated...
Mutation predicts chemotherapy resistance and better responses to immunotherapy in advanced bladder cancer
Researchers studied the KDM6A gene, which is altered in about 26% of advanced bladder cancers
Tumors with KDM6A mutations did not respond well...
Immunotherapy combination does not improve outcomes for patients with advanced anal cancer
Phase II ETCTN trial found ipilimumab plus nivolumab did not improve outcomes over nivolumab alone in...
Targeted therapy plus immunotherapy improved outcomes in advanced metastatic colorectal cancer
Phase III COMMIT trial evaluated better first-line options for patients with dMMR/MSI-H metastatic colorectal cancer
The study compared the immunotherapy atezolizumab alone versus mFOLFOX6/bevacizumab plus atezolizumab as first-line treatment
Median progression-free survival was 30 months for patients treated with combination therapy compared to 4.3 months for those receiving&...
